drugset
drugset / Trial / NCT05086276

FX-322 in Adults With Acquired Sensorineural Hearing Loss

NCT05086276 ↗

Phase 2 Completed 142 enrolled Frequency Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

Timeline

Start
2021-10-12
Primary completion
2022-12-30
Completion
2022-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator FX-322 Unknown — Other

Indications

noise induced hearing loss sensorineural hearing loss disorder sudden hearing loss disorder